🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Bristol-Myers Squibb stock gains on FDA approval of schizophrenia treatment

Published 27/09/2024, 10:16 pm
© Reuters.
BMY
-

Investing.com -- Bristol-Myers Squibb (NYSE:BMY) shares rallied 4.45% in premarket trading Friday following the announcement that the U.S. Food and Drug Administration (FDA) approved the company's new schizophrenia treatment, COBENFY.

The drug, which combines xanomeline and trospium chloride, represents a major breakthrough, with the company claiming it is the first new pharmacological approach to treat schizophrenia in decades.

COBENFY is a muscarinic agonist that targets M1 and M4 receptors, offering a new mechanism of action distinct from current therapies.

Chris Boerner, CEO of Bristol-Myers Squibb, described the approval as a "landmark."

"After more than 30 years, there is now an entirely new pharmacological approach for schizophrenia — one that has the potential to change the treatment paradigm," he said in a statement.

The approval is based on data from the EMERGENT clinical program, which demonstrated "significant reductions of schizophrenia symptoms compared to placebo."

The drug is also said to have a favorable safety profile. Analysts see this as a positive development for COBENFY's market potential.

Barclays (LON:BARC) analysts said the news validates the company's acquisition of Karuna and gives "Bristol another key top-line driver over the
balance of the decade."

They added that the drug's list price of $1,850 per month (~$22,500 annually) suggests potential upside beyond their initial expectations.

Truist analysts emphasized the first-in-class status of COBENFY, noting that it is the first new mechanism of action approved for schizophrenia in over 30 years.

They estimate that the drug could generate $4.2 billion in peak sales, surpassing the consensus estimate of $3.9 billion. The analysts also highlighted Bristol-Myers' future plans to expand COBENFY's indications to include Alzheimer's-related psychosis and bipolar disorder.

Meanwhile, BMO Capital told investors in a note that the news is a "significant positive for BMY shares."

"Today's announcement validates Bristol's $12.7B acquisition of Karuna and allows the company to start changing the narrative around the ongoing triple patent-cliff," said BMO Capital. "Following today's approval we estimate $2.4B in peak sales for COBENFY in Schizophrenia and $3.9B in Alz psychosis, pushing our target to $53/share."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.